FindTrial
Sign In

Predictive modeling of the efficacy of PD-1 inhibitors in the treatment of non-small cell lung cancer based on an inflammatory response scoring system

Predictive modeling of the efficacy of PD-1 inhibitors in the treatment of non-small cell lung cancer based on an inflammatory response scoring system

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098457
Enrollment
Unknown
Registered
2025-03-07
Start date
2025-03-11
Completion date
Unknown
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Disease Control :None
Disease Progress:None

Sponsors

The First Affiliated Hospital of Shihezi University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1 Age >= 18 years; 2 Pathologically confirmed diagnosis of non-small cell lung cancer; 3 Receiving PD-1 inhibitor therapy; 4 ECOG/PS score <3; 5 Informed consent; 6 Complete clinical data retention and follow-up.

Exclusion criteria

Exclusion criteria: 1 Combination of immune diseases or acute or chronic infections and other diseases that may affect the inflammatory index; 2 less than one cycle of treatment regimen; 3 pregnancy or serious infections; 4 combination of severe hepatic and renal insufficiency; 5 combination of other serious malignant tumors; 6 transfusion therapy; 7 cognitive disorders or psychiatric anomalies.

Design outcomes

Primary

MeasureTime frame
Progression Free Survival, PFS;—

Secondary

MeasureTime frame
Overall survival, OS;—

Countries

China

Contacts

Public ContactHanjing Li

Shihezi University

2770026757@qq.com+86 166 9904 9212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026